NASDAQ · ASLN
ASLAN Pharmaceuticals Limited
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
Loading market information…
NASDAQ · PTE · USD
Stock price, dividends, earnings
Quote as of Jun 15, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PolarityTE, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
PolarityTE, Inc.’s forward annual dividend is $2,620.80 per share, paid weekly. The forward yield is 1,087,468.88% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PolarityTE, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Salt Lake City, Utah, PolarityTE, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of regenerative tissue products and biomaterials. Its offerings serve the medical, biomedical engineering, and material sciences sectors across the United States. The company operates through two primary divisions: Regenerative Medicine Products and Contract Services. PolarityTE's key product is SkinTE, a specialized tissue solution employed for the repair, reconstruction, replacement, or augmentation of skin in patients. Its applications encompass treating acute or chronic wounds, burns, surgical reconstruction, scar revision, and the removal of dysfunctional skin grafts. In addition to its product line, the firm also provides contract research services. The company's pipeline includes SkinTE Cryo, which facilitates multiple deployments from a single harvest through a cryopreservation process, and a SkinTE point-of-care device designed for immediate processing and application of SkinTE directly after initial harvest. PolarityTE is also advancing PTE 11000, an allogenic, biologically active dressing engineered to accelerate healing in both wound care and aesthetic contexts, alongside other promising tissue regeneration products.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:59 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2021 | Aug 12, 2021 | -$1.50+50.0% vs estimate | $2.54M0.0% vs estimate |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$0.25-$0.09 (-27.68%)
Notable Labs, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
$0.85-$0.26 (-23.42%)
Fresh2 Group Limited’s quoted price sits in the lower half of its reported 52-week range, 90.56% below the high.
$0.29-$0.06 (-18.5%)
Midatech Pharma plc’s quoted price sits in the lower half of its reported 52-week range, 98.63% below the high.
$0.07-$0.07 (-50.87%)
VBI Vaccines Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.16% below the high.
$0.53-$0.17 (-24.12%)
Oncternal Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.04% below the high.
$0.38-$0.01 (-1.56%)
NeuBase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.49% below the high.
$0.34+$0.00 (+0.74%)
Timber Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.89% below the high.
